ATH-1017 for Alzheimer's Disease

(LIFT-AD Trial)

Recruiting in Palo Alto (17 mi)

+51 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Athira Pharma

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial tests a new drug called fosgonimeton to see if it can help people with mild to moderate Alzheimer's disease think more clearly and perform daily activities better.

Research Team

Javier San Martin, MD

Principal Investigator

Chief Medical Officer

Eligibility Criteria

Inclusion Criteria

You are not currently taking a drug called memantine (Namenda).

You have been diagnosed by a doctor with mild or moderate Alzheimer's disease.

You are not currently enrolled in another study testing an experimental treatment.

Exclusion Criteria

Treatment Details

Interventions

• ATH-1017 (Other)
• Placebo (Other)

Participant Groups

Group I: Dosage Experimental Treatment 1 Intervention

Daily subcutaneous (SC) injection of 40mg ATH-1017

Group II: Placebo Placebo Group 1 Intervention

Daily subcutaneous (SC) injection of Placebo

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Merritt Island Medical Research Merritt Island, FL

K2 Medical Research Maitland Orlando, FL

Global Medical Institutes LLC; Princeton Medical Institute Princeton, NJ

Berman Clinical New York, NY

More Trial Locations

Who Is Running the Clinical Trial?

Athira Pharma

Lead Sponsor

Trials

8

Patients Recruited

1,300+